David Cory Net Worth

The estimated Net Worth of David A Cory is at least $2.99 Milion dollars as of 25 April 2019. Mr. Cory owns over 343 units of Eiger BioPharmaceuticals Inc stock worth over $114,447 and over the last 9 years he sold EIGR stock worth over $0. In addition, he makes $2,871,850 as President, Chief Executive Officer oraz Director at Eiger BioPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cory EIGR stock SEC Form 4 insiders trading

David has made over 3 trades of the Eiger BioPharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 343 units of EIGR stock worth $3,862 on 25 April 2019.

The largest trade he's ever made was buying 1,562 units of Eiger BioPharmaceuticals Inc stock on 18 August 2016 worth over $24,523. On average, David trades about 164 units every 75 days since 2016. As of 25 April 2019 he still owns at least 66,346 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Mr. Cory stock trades at the bottom of the page.

David Cory biography

David A. Cory serves as President, Chief Executive Officer, Director of the Company. He has been the President and Chief Executive Officer of Eiger since 2009. Prior to working at Eiger, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.

What is the salary of David Cory?

As the President, Chief Executive Officer oraz Director of Eiger BioPharmaceuticals Inc, the total compensation of David Cory at Eiger BioPharmaceuticals Inc is $2,871,850. There are no executives at Eiger BioPharmaceuticals Inc getting paid more.

How old is David Cory?

David Cory is 56, he's been the President, Chief Executive Officer oraz Director of Eiger BioPharmaceuticals Inc since 2016. There are 9 older and 7 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.

What's David Cory's mailing address?

David's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman oraz Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Mr. Cory stock trades at Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,